Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy

Completed · Phase 2 · Has a placebo group

Conditions studied: Proliferative Diabetic Retinopathy

In brief

To evaluate the effects of oral emixustat hydrochloride (emixustat) on aqueous humor biomarkers associated with proliferative diabetic retinopathy (PDR) from baseline to week 12.

Key facts

Study ID

NCT02753400

Run by

Kubota Vision Inc.

People needed

24

Starts

2016-05-01

Expected to finish

2017-12-01

Last updated by the study team

2021-05-19

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Able and willing to provide written informed consent
• Documented diagnosis of type 1 or type 2 diabetes mellitus
• Meets specific ocular criteria for the study eye including but not limited to, the presence of PDR with or without diabetic macular edema in study eye for which treatment can be deferred for at least 4 weeks after Day 1 visit
• Media clarity, pupillary dilation, and subject cooperation sufficient to obtain adequate assessments

You may not qualify if…

• Any condition that would preclude participation in the study (e.g., unstable medical status including blood pressure, cardiovascular disease or glycemic control)
• History of myocardial infarction or other acute cardiac event
• History of chronic renal failure requiring dialysis or kidney transplant
• Prior participation in any clinical study of emixustat
• Treatment with any investigational study drug within 30 days of screening
• Known allergy to fluorescein sodium for injection in angiography
• Treatment with specific prohibited medications or therapy beginning 4 weeks prior to screening and throughout the duration of the study
• History of systemic anti-VEGF or pro-VEGF treatment within 4 months prior to randomization
• Pre-specified laboratory abnormalities at screening
• Specific ocular characteristics in the study eye
• Male subjects who are not surgically sterile and are not willing to practice a medically accepted method of birth control with their female partner of childbearing potential from screening through 30 days following completion of the study
• Female subjects of childbearing potential who are not willing to practice a medically accepted method of birth control with their non-surgically sterile male sexual partner from screening through 30 days following completion of the study
• Female subjects who are pregnant or lactating

Where it is running

• Retina Institute of California — Arcadia, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.